NXTS$0.5466+2.86%
Nexentis Technologies Inc.
Sector: Pharmaceutical PreparationsIndustry: Agricultural InputsCountry: ILExchange: Nasdaq
Mkt Cap:$1.32M
Float & O/S:
Inst Own:
DilutionScan read 36 of Nexentis Technologies Inc.'s SEC filings and found 6 warrant series, 1 convertible, 2 equity lines, 1 shelf registration, 2 S-1 registrations and 3 completed offerings on file for NXTS. The latest dilution event on file is a registration statement on Jul 17, 2026. Analysis updated Oct 19, 2026.
Signal8 Summary
NXTS
Zero revenue and short cash runway
Snapshot
N2OFF is a distressed micro-cap that generated zero revenue in FY 2025 while reporting a net loss of $4.0M. The company burns cash at a rate of $3.8M per year, which gives it a cash runway of roughly seven months.
What's Happening Right Now
- : Nexentis announced an AI drug discovery initiative between its subsidiary MitoCareX Bio and Boltz PBC to combine their technologies for virtual screening.
- : MitoCareX Bio generated an optimized hit molecule with improved pharmaceutical properties, marking its first drug discovery milestone since acquisition.
- : The company received U.S. trademark registration for its MITOLINE algorithm platform used for 3D modeling of mitochondrial proteins.
